Irinotel

Irinotel

irinotecan

Manufacturer:

Fresenius Kabi

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Irinotecan HCl trihydrate
Indications/Uses
Patients w/ metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU therapy. Non-small & small cell lung cancer, cervical, ovarian & esophageal cancer, malignant glioma & inoperable or recurrent gastric cancer.
Dosage/Direction for Use
Metastatic carcinoma of the colon & rectum Monotherapy: 350 mg/m2 over 90 min infusion every 3 wk. Combination w/ 5-FU, w/ or w/o folinic acid: 180 mg/m2 every 2 wk. Other indicated cancer Combination w/ cisplatin: 65 mg/m2 & cisplatin 30 mg/m2 in repeated 6-wk cycle, comprising wkly followed by a 2-wk rest.
Contraindications
Hypersensitivity to irinotecan, topotecan or other camptothecin analogues. Pregnancy.
Special Precautions
Diarrhea; renal & hepatic impairment; history of bleeding disorder; carcinogenicity, mutagenicity, impairment of fertility.
Adverse Reactions
Bone marrow suppression, diarrhea, flushing, insomnia, dizziness, pulmonary toxicity, alopecia, skin rash, asthenia, fever, abdominal pain, nausea & vomiting.
Drug Interactions
Live vaccine. Prochlorperazine.
ATC Classification
L01CE02 - irinotecan ; Belongs to the class of Topoisomerase 1 (TOP1) inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Irinotel infusion 300 mg/15 mL
Packing/Price
1's
Form
Irinotel infusion 40 mg/2 mL
Packing/Price
1's
Form
Irinotel infusion 100 mg/5 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in